BORJE S. ANDERSSON, M.D.,PHD
Osteopathic Medicine at Holcombe Blvd, Houston, TX

6444872, Sep 3, 2002

Aug 18, 2000

09/642397

Borje S. Andersson - Houston TX
Taraneh K. Sadeghi - Houston TX
Douglas M. Cromeens - Spring TX
Jeffrey J. Tarrand - Houston TX

Board of Regents, The University of Texas System - Austin TX

A01K 6700

800 11, 800 14, 424423, 435 4, 435 72, 435 731

A model of systemic mold/Aspergillus infection in a profoundly immunocompromised host has been established in the beagle dog. The beagle was rendered immunosuppressed using a combination of total body irradiation and daily steroids, which provided a window of time where the mold could be successfully inoculated through a bronchoscope. This created a localized infection in one lung lobe, which subsequently spread diffusely throughout the lung parenchyma, and uniformly resulted in the animals death. The invention contemplates the further study of the pathophysiology of opportunistic mold infections in vivo and also provides examples for the development of new antifungal agents and more effective combinations of agents. Finally, the invention contemplates the development of technology for the early detection of systemic mold infections. The inventors envision, that the use of the model should help save patients from clinical trials of antifungal drugs that may be effective in vitro without living up to the expectations in a clinical setting.

6045815, Apr 4, 2000

Aug 15, 1997

8/911607

Borje S. Andersson - Houston TX
Elias J. Anaissie - Little Rock AR

Board of Regents, The University of Texas System - Austin TX

A01N 2502, A61K 9107

424405

An antifungal composition suitable for parenteral administration to a mammal includes an amount of pimaricin or an antifungal derivative thereof that is effective to inhibit the growth of a fungal infection in a mammal; a pharmaceutically acceptable dipolar aprotic solvent; and a pharmaceutically acceptable aqueous secondary solvent. The composition can be used in methods of preventing or treating a systemic fungal infection in a mammal. The composition can be prepared by dissolving pimaricin or an antifungal derivative thereof in the pharmaceutically acceptable dipolar aprotic solvent; adding to the solution a pharmaceutically acceptable aqueous secondary solvent; and in a preferred method, by subsequently lypohilizing the composition, whereby a dry, shelf-stable composition is produced. This dry composition can be reconstituted into an aqueous solution suitable for parenteral administration.

2014003, Jan 30, 2014

Dec 16, 2011

13/994152

Borje S. Andersson - Houston TX, US
Jeffrey Tarrand - Houston TX, US
Benigno C. Valdez - Missouri City TX, US

Board of Regents, The University of Texas System - Austin TX

A61K 31/496, A61K 9/00

51425407

A parenteral azole composition comprises a first solvent, made of benzyl alcohol and/or an acidified alcohol such as ethanol, and a lipophilic component such as PEG400, and the azole, or triazole, such as itraconazole or posaconazole dissolved in this first composite solvent vehicle that is essentially free of surfactants, particularly non-ionic surfactants, and has low levels of water, preferably less than 5% water. The composition may be further diluted with an infusion fluid, such as normal saline or 5% or 10% dextrose in water, before infusion into an immunocompromized mammal, preferably a human. The composition is useful for the treatment and suppression of infections caused by microbes such as yeast and molds that are sensitive to azoles, but it may be extended to dissolve other pharmaceutically active agents that can be used to treat other types of infectious diseases or other ailments, such as malignant and autoimmune diseases.

2012027, Nov 1, 2012

Apr 20, 2012

13/452033

Borje S. Andersson - Houston TX, US
Benigno C. Valdez - Missouri City TX, US
Jeffrey Tarrand - Houston TX, US

A61K 31/255, A61P 31/10, A61P 25/24, A61P 31/12, A61P 25/18, A61K 31/496, A61P 31/04

51425407, 514517

There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as PEG400 but essentially free of organic solvents and non-solubilized particles. The composition may be further diluted with a desired aqueous diluent such as an infusion fluid for parenteral administration to a subject such as a human. The compositions may be useful for the treatment for diseases or conditions that are sensitive to lipophilic agents, such as infectious diseases, malignant or autoimmune diseases.

7153838, Dec 26, 2006

Oct 8, 1999

09/415890

Borje S. Andersson - Houston TX, US
Elias J. Anaissie - Little Rock AR, US

Board of Regents, the University of Texas System - Austin TX

A61K 31/7008, A61K 9/07, A61K 25/02

514 31, 424405, 424406, 424450, 514937, 514938, 514970, 514974

An antifungal composition suitable for parenteral administration to a mammal includes an amount of pimaricin or an antifungal derivative thereof that is effective to inhibit the growth of a fungal infection in a mammal; a pharmaceutically acceptable dipolar aprotic solvent; and a pharmaceutically acceptable aqueous secondary solvent. The composition can be used in methods of preventing or treating a systemic fungal infection in a mammal. The composition can be prepared by dissolving pimaricin or an antifungal derivative thereof in the pharmaceutically acceptable dipolar aprotic solvent; adding to the solution a pharmaceutically acceptable aqueous secondary solvent; and in a preferred method, by subsequently lypohilizing the composition, whereby a dry, shelf-stable composition is produced. This dry composition can be reconstituted into an aqueous solution suitable for parenteral administration.

7220726, May 22, 2007

May 15, 2003

10/439252

Borje S. Andersson - Houston TX, US
Elias J. Anaissie - Little Rock AR, US

Board of Regents, The University of Texas System - Austin TX

A61K 31/7008, A61K 9/107, A61K 25/02

514 31, 424405, 424406, 424450, 514937, 514938, 514970, 514974

An antifungal composition suitable for parenteral administration to a mammal includes an amount of pimaricin or an antifungal derivative thereof that is effective to inhibit the growth of a fungal infection in a mammal; a pharmaceutically acceptable dipolar aprotic solvent; and a pharmaceutically acceptable aqueous secondary solvent. The composition can be used in methods of preventing or treating a systemic fungal infection in a mammal. The composition can be prepared by dissolving pimaricin or an antifungal derivative thereof in the pharmaceutically acceptable dipolar aprotic solvent; adding to the solution a pharmaceutically acceptable aqueous secondary solvent; and in a preferred method, by subsequently lypohilizing the composition, whereby a dry, shelf-stable composition is produced. This dry composition can be reconstituted into an aqueous solution suitable for parenteral administration.

5559148, Sep 24, 1996

May 24, 1995

8/449685

Borje S. Andersson - Houston TX
Harshal P. Bhagwatwar - Houston TX
Diana S. Chow - Houston TX

Board of Regents, The University of Texas System - Austin TX
University of Houston-University Park - Houston TX

A61K 31255

514517

Stable parenteral formulations of busulfan for parenteral administration are disclosed. The improved bioavailability of the parenteral formulations optimizes high dose busulfan therapy against malignant disease and improves the safety of such therapy.

6844004, Jan 18, 2005

Nov 14, 2002

10/294491

Borje S. Andersson - Houston TX, US

Board of Regents, The University of Texas System - Austin TX

A61K 910, A61K 3170, A61K 317048, A01N 2500, A01N 2502

424405, 424400, 424 701, 514 31

The present invention relates to formulations of Pimaricin (also called Natamycin), that are useful for the treatment and suppression of topical infections such as those caused by various pathogens including molds and yeast, that are resistant to azole compounds and to Amphotericin B. Methods for treatment of infections are also set forth.

5430057, Jul 4, 1995

Sep 30, 1993

8/129995

Borje S. Andersson - Houston TX
Harshal P. Bhagwatwar - Houston TX
Diana S. L. Chow - Houston TX

Board of Regents, The University of Texas System - Austin TX
University of Houston-University Park - Houston TX

A61K 31255

514517

Stable parenteral formulations of busulfan safe for parenteral administration are disclosed that exhibit improved bioavailability and optimize high dose busulfan therapy against malignant disease.